Sacituzumab govitEcan in THYroid Cancers

Clinical trial NCT06235216 · RECRUITING

Trial details

NCT number: NCT06235216
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Differentiated Thyroid Cancer Anaplastic Thyroid Cancer

Start date: 2024-09-13
Primary completion: 2027-12-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.